Literature DB >> 32016340

Impact of L4 lymph node dissection on long-term survival in left-side operable non-small-cell lung cancer: a propensity score matching study.

Mu-Zi Yang1,2, Xue Hou2,3, Ji-Bin Li2,4, Jing-Sheng Cai1,2, Jie Yang1,2, Shuo Li1,2, Hao Long1,2, Jian-Hua Fu1,2, Lan-Jun Zhang1,2, Peng Lin1,2, Tie-Hua Rong1,2, Hao-Xian Yang1,2.   

Abstract

OBJECTIVES: We investigated the impact of level 4 (L4) lymph node dissection (LND) on overall survival (OS) in left-side resectable non-small-cell lung cancer (NSCLC), with the aim of guiding lymphadenectomy.
METHODS: A total of 1929 patients with left-side NSCLC who underwent R0 resection between 2001 and 2014 were included in the study. The patients were divided into a group with L4 LND (L4 LND+) and a group without L4 LND (L4 LND-). Propensity score matching was applied to minimize selection bias. The Kaplan-Meier method and Cox proportional hazards model were used to assess the impact of L4 LND on OS.
RESULTS: A total of 317 pairs were matched. Of the cohort of patients, 20.3% (391/1929) had L4 LND. Of these patients, 11.8% (46/391) presented with L4 lymph node metastasis. L4 lymph node metastasis was not associated with the primary tumour lobes (P = 0.61). Before propensity score matching, the 5-year OS was comparable between the L4 LND+ and L4 LND- groups (69.0% vs 65.2%, P = 0.091). However, after propensity score matching, the 5-year OS of the L4 LND+ group was much improved compared to that of the L4 LND- group (72.9% vs 62.3%, P = 0.002) and L4 LND was an independent factor favouring OS (hazard ratio 0.678, 95% confidence interval 0.513-0.897; P = 0.006). Subgroup analysis suggested that L4 LND was an independent factor favouring OS in left upper lobe tumours.
CONCLUSIONS: In patients with left-side operable NSCLC, L4 lymph node metastasis was not rare and L4 LND should be routinely performed.
© The Author(s) 2020. Published by Oxford University Press on behalf of the European Association for Cardio-Thoracic Surgery. All rights reserved.

Entities:  

Keywords:  Lymph node dissection; Non-small-cell lung cancer; Surgery; Survival

Mesh:

Year:  2020        PMID: 32016340     DOI: 10.1093/ejcts/ezaa008

Source DB:  PubMed          Journal:  Eur J Cardiothorac Surg        ISSN: 1010-7940            Impact factor:   4.191


  5 in total

1.  Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?

Authors:  X Hou; M-Z Yang; J-B Li; Z-H Tan; H Long; J-H Fu; L-J Zhang; P Lin; H-X Yang
Journal:  ESMO Open       Date:  2022-06-07

2.  Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm.

Authors:  Run-Bin Liang; Peng Li; Bob T Li; Jie-Tian Jin; Valerie W Rusch; David R Jones; Yi-Long Wu; Qing Liu; Jie Yang; Mu-Zi Yang; Shuo Li; Hao Long; Jian-Hua Fu; Lan-Jun Zhang; Peng Lin; Tie-Hua Rong; Xue Hou; Su-Xia Lin; Hao-Xian Yang
Journal:  Chest       Date:  2021-03-18       Impact factor: 9.410

3.  Is major pathologic response sufficient to predict survival in resectable nonsmall-cell lung cancer patients receiving neoadjuvant chemotherapy?

Authors:  Jing-Sheng Cai; Shuo Li; Shu-Mei Yan; Jie Yang; Mu-Zi Yang; Chu-Long Xie; Ji-Bin Li; Yan-Fen Feng; Hao-Xian Yang; Xue Hou
Journal:  Thorac Cancer       Date:  2021-03-10       Impact factor: 3.500

4.  Station 3A lymph node dissection does not improve long-term survival in right-side operable non-small-cell lung cancer patients: A propensity score matching study.

Authors:  Mu-Zi Yang; Zi-Hui Tan; Ji-Bin Li; Hao Long; Jian-Hua Fu; Lan-Jun Zhang; Peng Lin; Xue Hou; Hao-Xian Yang
Journal:  Thorac Cancer       Date:  2022-06-15       Impact factor: 3.223

5.  Mediastinal lymph node evaluation, especially at station 4L, in left upper lobe lung cancer.

Authors:  Jun Hanaoka; Makoto Yoden; Keigo Okamoto; Ryosuke Kaku; Yasuhiko Ohshio
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.